Last reviewed · How we verify
Refresh Tears
At a glance
| Generic name | Refresh Tears |
|---|---|
| Also known as | REFRESH TEARS 0.1 fl oz, - from Allergan |
| Sponsor | Pharmaceutical Research Network |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease (PHASE3)
- A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes (PHASE3)
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease (PHASE3)
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study (PHASE1)
- Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests (PHASE4)
- The Role of Loteprednol in Reducing Post-Intravitreal Injection Related Pain (NA)
- The Effect of Eye Care With Artificial Tears and Normal Saline on Ocular Surface Disease in Mechanically Ventilated Pediatric Patients (NA)
- The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Refresh Tears CI brief — competitive landscape report
- Refresh Tears updates RSS · CI watch RSS
- Pharmaceutical Research Network portfolio CI